|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study**  | **Number of isolates** | **Serotype** | **Antimicrobials to which the isolates were resistant**  | **Resistance genes identified**  |
| CNS study | 2 | *Salmonella* Typhimurium | Ampicillin, ceftiofur, ceftriaxone, chloramphenicol, gentamycin, streptomycin, sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole. | *bla*CTX-M-15 , *bla*TEM-1, *bla*OXA-1, *cat*A1, *cat*B3, *aac*(3)*-IIa*, *str*AB, *aad*A24, *sul1, sul2*, *tet*A, *dfrA1*, *dfrA14*, *aac(6')lb-cr* |
|  |  |  |  |  |
| Surveillance program  | 2 | *Salmonella* Typhimurium | Ampicillin, ceftiofur, ceftriaxone, chloramphenicol, gentamycin, streptomycin, sulfisoxazole, tetracycline, trimethoprim-sulfamethoxazole, ciprofloxacin and nalidixic acid. | *bla*CTX-M-15 , *bla*TEM-1, *bla*OXA-1, *cat*A1, *cat*B3, *aac*(3)*-IIa*, *str*AB, *aad*A24, *sul1, sul2*, *tet*A, *dfrA1*, *dfrA14*, *aac(6')lb-cr*, *gyrA* |

**S4 Table. Serotyping and whole genome sequencing results of 4 selected non-typhoidal *Salmonella* isolates from invasive infections identified among central nervous system infection study (CNS study), and International Emerging Infections Program (surveillance program) participants during 2009–2014, Siaya county, Kenya**